Article
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives.
Expert review of anticancer therapy - 1 Oct 2013
Costanzo Raffaele, Montanino Agnese, Di Maio Massimo, Piccirillo Maria Carmela, Sandomenico Claudia, Giordano Pasqualina, Daniele Gennaro, Franco Renato, Perrone Francesco, Rocco Gaetano, Normanno Nicola, Morabito Alessandro
Abstract excerpt
The identification of activating mutations in the tyrosine kinase domain of the EGF receptor (EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic revolution in the treatment of patients with metastatic non-small-cell lung cancer (NSCLC). To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.